

# 1 The neurodevelopmental spectrum of *CASK*-related disorder

2 Jessica Martin<sup>1</sup>, Alkistis Mavrogalou-Foti<sup>1</sup>, Josefine Eck<sup>1</sup>, Laura Hattersley<sup>2</sup>, Kate Baker<sup>1, 3, 4</sup>

3 <sup>1</sup>MRC Cognition and Brain Sciences Unit, University of Cambridge

4 <sup>2</sup>CASK Research Foundation

5 <sup>3</sup>Department of Medical Genetics, University of Cambridge

6 <sup>4</sup>Department of Pathology, University of Cambridge

7 \*Correspondence to Kate Baker: [kate.baker@mrc-cbu.cam.ac.uk](mailto:kate.baker@mrc-cbu.cam.ac.uk)

## 8 Abstract

9 Background: Pathogenic *CASK* variants are associated with neurodevelopmental disorders of  
10 variable severity including X-linked intellectual disability (XLID) and microcephaly with  
11 pontocerebellar hypoplasia (MICPCH). Although the number of diagnosed cases is rising, current  
12 understanding of the *CASK*-related neurodevelopmental spectrum is limited. Here, we systematically  
13 review the published characteristics of individuals with *CASK*-related disorder, and compare these to  
14 a more recently-diagnosed group. We provide quantitative information about the ranges of adaptive  
15 abilities, motor function, visual function and social-emotional-behavioural characteristics, and  
16 explore within-group associations.

17 Methods: 151 individuals with *CASK* variants were identified in published literature. 31 children and  
18 young people with *CASK* variants were recruited to the UK-based Brain and Behaviour in  
19 Neurodevelopmental disorder of Genetic Origin (BINGO) project. BINGO-participating caregivers  
20 completed a bespoke medical history questionnaire and battery of standardised  
21 neurodevelopmental measures.

22 Results: Comparing the recently diagnosed BINGO *CASK*-related disorder group to previously  
23 reported individuals, we found consistent prevalence of tone abnormalities, sensorineural hearing  
24 loss and epilepsy, but lower prevalence of severe/profound ID, MICPCH, optic atrophy and  
25 nystagmus. Areas of frequent difficulty not highlighted in previous reports include sleep difficulties  
26 and cerebral visual impairment (CVI). Neurodevelopmental characteristics were highly variable  
27 within the BINGO *CASK*-related disorder group, and group-wide patterns were similar to those  
28 observed in other rare genetic conditions. Within the BINGO *CASK*-related group, epilepsy is  
29 significantly associated with ID severity, after controlling for age. Sub-groups with MICPCH or  
30 microcephaly only have equivalent ranges of adaptive function, but MICPCH may be associated with  
31 more severe motor difficulties.

32 Conclusion: The spectrum of neurodevelopmental characteristics associated with *CASK*-related  
33 disorder appears to be broadening with increased access to genome-wide diagnostic testing.  
34 Further studies are needed to elucidate the relationships between *CASK* variants, structural brain  
35 development, epilepsy, and neurodevelopmental characteristics.

## 36 Keywords

37 *CASK*-related disorder, X-linked Intellectual Disability, MICPCH, Epilepsy, Autism characteristics,  
38 Adaptive function, Cerebral Visual Impairment, Genetic, Sleep difficulties

## 39 Background

40 Calcium/calmodium-dependent serine protein kinase (CASK) is a multi-domain scaffolding protein  
41 and a member of the membrane-associated guanylate kinase (MAGUK) family, with diverse neuronal  
42 functions (reviewed in 1). Several neurodevelopmental presentations have been reported in  
43 association with *CASK* variants including: X-linked intellectual disability (XLID) (2,3), microcephaly  
44 with pontine and cerebellar hypoplasia (MICPCH) (4–6), XLID with or without nystagmus and  
45 microcephaly (7,8), X-linked optic and ophthalmic problems (9), and FG syndrome (10,11). Prior to  
46 next generation sequencing (NGS) diagnostics, most individuals with *CASK*-related diagnoses were  
47 identified phenotype-first based on these descriptions. With the application of genotype-first NGS  
48 diagnostic approaches and broader ascertainment of individuals with neurodevelopmental  
49 presentations for clinical genetic testing, the number of individuals diagnosed with a *CASK*-related  
50 disorder is rising. Consequently, the reported *CASK*-associated phenotypic spectrum may not be fully  
51 representative. There is an urgent need for an up-to-date phenotypic evidence base which can  
52 contribute to variant interpretation and provide accurate information about the nature and range of  
53 long-term challenges faced by this patient group.

54 In particular, there has been limited characterisation of cognitive, adaptive, behavioural and social-  
55 emotional functions within *CASK*-related disorder. Almost all reported individuals have  
56 developmental delay and intellectual disability (ID) (12), and there have been several reported cases  
57 of autism spectrum disorder (ASD) and autism-related traits (13–16). However, no systematic  
58 evaluation of neurodevelopmental domains has been published. Standardised measures of motor  
59 function, communication and social-emotional functions appropriate for individuals with ID have not  
60 been included within any case series.

61 Additionally, the factors predicting neurodevelopmental variation within *CASK*-related disorder are  
62 unclear. Truncating and missense variants have been associated with more severe and less severe  
63 presentations respectively, with males being more severely affected than females within either

64 variant group (12). However, there are exceptions to this pattern, such as a nonsense variant  
65 identified in a mildly affected male patient (14) and missense variants identified in severely affected  
66 females (17,18). Moreover, gender and variant type cannot enable precise predictions of ID severity,  
67 because the majority of *CASK*-diagnosed individuals are female and have truncating variants. Beyond  
68 genotype, the presence and extent of neuroanatomical abnormalities could be another predictor of  
69 neurodevelopmental variation. For example, a relationship has been observed between more severe  
70 MRI findings (i.e., MICPCH) and a more severe clinical presentation (i.e., epilepsy, ophthalmologic,  
71 motor and speech problems), in males but not females with *CASK* variants (19,20). Another potential  
72 within-group influence on neurodevelopment could be epilepsy, which affects around 50% of  
73 individuals with a *CASK* variant (21,22), and can predict developmental abilities in other monogenic  
74 conditions (23–26). One preliminary study in *CASK*-associated disorder did not find evidence for a  
75 link between epilepsy characteristics and severity of developmental delay (21), but variant type and  
76 gender may be confounding factors.

77 In this paper, we aim to address these gaps and provide a comprehensive phenotypic description of  
78 *CASK*-related disorder. First, we present a structured review of published clinical case series, to  
79 provide a benchmark for comparison to 31 individuals with *CASK* variants assessed via a structured  
80 parent-report questionnaire within a wider research study (BINGO – Brain and Behaviour in  
81 Neurodevelopmental disorders of Genetic Origin). This comparison enables us to establish whether  
82 the *CASK*-related phenotypic spectrum is changing in parallel with broader ascertainment and  
83 genotype-first diagnostics. Second, we present standardised multi-domain neurodevelopmental data  
84 for the BINGO *CASK* participant group, to document their range of abilities and difficulties, including  
85 relationships between domains. Third, we explore whether neurodevelopmental variation within  
86 this group is associated with neuroanatomical abnormalities or epilepsy.

## 87 **Methods**

### 88 **Literature Review**

89 We conducted a review of literature describing the clinical features of individuals with *CASK*-related  
90 disorder. Relevant literature published up until May 2024 was identified on Medline (PubMed) and  
91 Google Scholar using the search terms “*CASK*”, “*CASK*-related disorders”, “microcephaly”, “MICPCH”,  
92 and “pontocerebellar hypoplasia”. Additional papers were identified from bibliographies. We  
93 included case series that reported (A) at least three individuals with *CASK*-related disorder who had  
94 not been previously described and (B) clinical characteristics assessed via direct evaluation or  
95 retrospective review of available medical records. Using these inclusion criteria, we identified 15  
96 papers. We excluded Hayashi et al. (2012)(4) from the review as all individuals were later described  
97 in Takanashi et al., (2012)(27). Individuals previously described in Valayannopoulos et al., (2012)(28)  
98 and Takanashi et al., (2012)(27) were also excluded from our summary of Burglen et al., (2012)(19)  
99 and Hayashi et al., (2017)(5), respectively. Thus, our review includes 14 papers and, to the best of  
100 our knowledge, summarises unique individuals with *CASK*-related disorder.

## 101 [BINGO data collection](#)

### 102 [Participants](#)

103 Children and young people (CYPs) with *CASK*-related disorder were recruited to BINGO via an  
104 international network of *CASK*-related charities (*CASK* Research Foundation, Angelina *CASK*  
105 Neurological Research Foundation, Association Enfants *CASK* France), UK-based charities for rare  
106 conditions (Unique, Cambridge Rare Disease Network, Genetic Alliance UK), and regional genetic  
107 services in the UK. CYPs were eligible if they were aged at least 3 years old, experienced  
108 neurodevelopmental difficulties, and had a pathogenic or likely pathogenic *CASK* gene variant, or a  
109 variant of uncertain significance, which was previously fed-back via a clinical genetic services as likely  
110 related to clinical presentation. Genetic diagnoses were confirmed via medical records. *CASK*  
111 variants were classified as single nucleotide variants (SNVs) or copy number variants (CNVs). SNVs  
112 were annotated as either (a) protein-truncating, (b) intronic or (c) missense variants; CNVs were

113 annotated as either (a) intragenic or (b) multi-gene in line with previous literature on pathogenic  
114 *CASK* genotypes.

## 115 Phenotyping methods

116 Parent-report questionnaires were completed online, by post, or via Zoom or telephone interview  
117 according to parent preference. Clinical information was gathered via a study-specific medical  
118 history questionnaire (MHQ) covering prenatal, infancy and childhood health, plus acquisition of  
119 developmental milestones. Information regarding structural brain abnormalities was obtained via  
120 Magnetic Resonance Imaging reports (MRI;  $n = 14$ ), genetic test reports ( $n = 9$ ) and parental reports  
121 ( $n = 2$ ). Standardised neurodevelopmental questionnaires and procedures for scoring and analysis  
122 are described in Supplementary Table 1.

## 123 Statistical analysis

124 BINGO data were analysed using R studio, version 2023.3.0.386. Where participants had partial  
125 datasets, all available data were included in analyses. Raincloud plots were generated for each  
126 questionnaire measure. Cut-off scores were overlaid on each raincloud plot where possible to  
127 contextualise the severity of difficulties in *CASK*-related disorder relative to normative populations,  
128 or previously reported literature. Within-sample relationships were explored between demographic  
129 (age, sex), neurological (epilepsy), developmental (Vinland Adaptive Behaviour Scales (VABS; 29)  
130 composite score, Flemish Cerebral Visual Impairment Questionnaire (FCVIQ; 30) total score, and  
131 social-emotional-behavioural (total scores on the Social Responsiveness Scale (SRS-2; 31), the  
132 Developmental Behaviour Checklist (DBC2; 32), and the Repetitive Behaviour Questionnaire (RBQ;  
133 33)) characteristics using statistical tests appropriate to data type. Non-parametric methods were  
134 selected if data violated the assumption of normality, and Kendall's tau correlation was chosen over  
135 Spearman's rank correlation if ties represented more than 20% of the data. To reduce the likelihood  
136 of type I errors, p-values were adjusted for multiple testing by applying a Benjamini-Hochberg False  
137 Discovery Rate (B-H FDR) correction. Regression analyses were used to examine the influence of

138 epilepsy on adaptive function (VABS composite score). The assumptions of regression were tested  
139 prior to analyses (Supplementary Table 6a and 7a). Descriptive differences were explored between  
140 CYPs with different neuroanatomical abnormalities (MICPCH vs. microcephaly only vs. no  
141 abnormalities reported). Variables explored were demographic characteristics, VABS composite  
142 scores and VABS motor domain scores, FCVIQ total scores and epilepsy prevalence.

## 143 Results

### 144 Review of published cases

145 Supplementary Table 2 summarises the clinical characteristics of 151 individuals carrying *CASK*  
146 variants, reported in previous publications. The majority were female (72.2%) and age ranged from 2  
147 weeks to 49 years old at the time of reporting. SNVs accounted for 71.5% of *CASK* variants,  
148 encompassing protein-truncating (44.4%), intronic (35.2%), and missense (20.4%) variants. CNVs  
149 (28.5%) included both intragenic (48.8%) and multi-gene (51.2%) deletions of varying sizes. De novo  
150 variants (77.3%) were more common than inherited variants (22.7%).

151 The most frequently reported clinical problems were feeding difficulties (57.1%), including  
152 gastroesophageal reflux, sucking and swallowing difficulties. Interventions such as thickened  
153 liquids/pureed foods, nasogastric tube or gastrostomy were common, although feeding difficulties  
154 were noted to improve with age in some individuals (1,20). Tone abnormalities were also frequent,  
155 including hypotonia (57.1%), hypertonia (41.8%) or mixed tone abnormalities (14%). Epilepsy was  
156 reported in 48.9% overall. Seizure details were inconsistently reported, but a range of seizure types  
157 were described, including early infantile epileptic encephalopathies with variable EEG phenotypes  
158 (e.g., West Syndrome, Ohtahara syndrome), infantile spasms, later-onset epilepsies (generalised or  
159 focal) and myoclonic epilepsies. Many individuals had mixed seizure types and there was a variable  
160 response to anti-seizure medications from remission to intractable. Optic atrophy (28.6%),  
161 strabismus (30.4%) and nystagmus (25%) were common ophthalmological abnormalities co-



It is made available under a [CC-BY 4.0 International license](#) .

162 occurring with each other. Other reported vision-related phenotypes included astigmatism, myopia,  
163 hyperopia, retinopathy, glaucoma and cerebral visual impairment (CVI). Sensorineural hearing loss  
164 was present in 24.6%. Other characteristics less frequently reported were scoliosis, kidney problems  
165 and sleep disturbances.

166 The majority of reported individuals with *CASK*-related disorder had severe or profound  
167 developmental delay (88%). 56.6% were able to sit without support and acquired this ability  
168 between 6 months and 3 years. Fewer individuals (25.7%) had acquired the ability to walk  
169 independently with age of acquisition ranging from 18 months to 6 years. There were also three  
170 reports of regression of motor abilities, including a case of mild regression at 2 years (6), an  
171 individual that lost ability to walk at 25 years after severe febrile seizures (1), and an individual that  
172 lost ability to sit after scoliosis surgery (14). A minority of individuals were reported to use some  
173 vocal communication (33.8%), which ranged from babbling and vocalisations to short sentences.  
174 Two papers reported individuals using Augmentative and Alternative Communication (AAC) systems  
175 as non-verbal methods of communication, such as an eye gaze device and Picture Exchange  
176 Communication System (PECS; 14,19).

177 In the papers we identified, there was a limited focus on social, emotional and behavioural problems  
178 with only four papers describing social or emotional-behavioural difficulties, such as ASD (1,14), self-  
179 injurious behaviours (19) and general behavioural difficulties (28).

180 Where MRI data were reported, the majority of individuals with *CASK* variants had MICPCH (87.1%).  
181 There were also five individuals with cerebellar and/or pontine hypoplasia only (3.6%), four  
182 individuals with microcephaly and other brain abnormalities (2.9%), three cases of microcephaly  
183 with cerebellar hypoplasia only (2.1%), three of microcephaly only (2.1%), and three reports of no  
184 brain abnormalities (2.1%).

185 [Comparison between reviewed cases and BINGO \*CASK\*-related group](#)

It is made available under a [CC-BY 4.0 International license](#) .

186 Thirty-one CYPs with *CASK*-related disorder participated in BINGO and were included in this analysis.  
187 Comparison between demographic and clinical characteristics of BINGO participants and the  
188 reviewed population is summarised in Table 1. A higher proportion of the BINGO group were female,  
189 and the age range was narrower due to an age limit for BINGO eligibility. The proportion of  
190 individuals with either *CASK* SNVs or CNVs were near identical between reviewed cases and BINGO,  
191 although the BINGO group contained a higher proportion of truncating SNVs versus missense SNVs,  
192 and higher proportion of intragenic versus multi-gene CNVs. There were fewer reports of MICPCH in  
193 the BINGO group (44.0% vs. 87.1%) and more reports of microcephaly only (32.0% vs. 2.1%).

194 A higher percentage of feeding difficulties was reported in BINGO (83.9% vs. 57.1%), but the range of  
195 difficulties and interventions reported were similar to the reviewed group. The frequency of  
196 reported tone abnormalities, sensorineural hearing loss and epilepsy were comparable between the  
197 BINGO group and reviewed group. A range of seizure types were reported in BINGO, including  
198 infantile spasms, myoclonic epilepsies, as well as focal, complex and absence seizures. The age of  
199 seizure onset varied from 4 months to 10 years. Reports of strabismus, refractive errors and CVI  
200 were similar between BINGO and reviewed cases, but optic atrophy and nystagmus were not  
201 common in the BINGO group (9.7% and 3.2%, respectively) compared to reviewed cases (28.6% and  
202 25%, respectively). Sleep difficulties were common in our sample (74.12% ever experienced) but  
203 were not widely reported in previous literature (see 19 for exception). Parents reported a range of  
204 sleep-associated problems including difficulty settling, regular waking, and need for more or less  
205 sleep than expected for age, as well as sleep apnoea.

206 There were notable differences between BINGO and the reviewed group in acquisition of  
207 developmental milestones, whereby a higher percentage of the BINGO group had acquired the  
208 ability to sit (87.1% vs. 56.6%) and walk (51.6% vs. 25.7%). Reported verbal abilities were similar  
209 across the two groups. Categorisation of ID severity also differed between groups, with a higher  
210 percentage of the BINGO group in the mild or moderate (60.7% vs. 12.0%) rather than severe (25.0%

211 vs. 75.0%) category, noting that this categorisation was based on VABS data in BINGO but clinical  
212 report in the reviewed sample.

213 INSERT TABLE 1

## 214 Neurodevelopmental variation within the BINGO CASK-related group

215 Figures 1-5 show the distribution of scores on neurodevelopmental and social-emotional-  
216 behavioural measures. VABS composite scores indicated that global adaptive ability ranged from  
217 mildly impaired to severely/profoundly impaired (Figure 1). Communication was the most affected  
218 subdomain, whereas Socialisation was a relative strength.

219 INSERT FIGURE 1

220 Scores on the SRS-2 revealed high levels of autism-related traits, varying in severity within the  
221 atypical range. CYPs with CASK-related disorder demonstrate relative strengths in social motivation  
222 on the SRS-2, compared to other social subscales or Restricted and Repetitive Behaviours (Figure 2).  
223 These patterns are overall similar to observations in other rare genetic conditions (34,35). The  
224 majority of DBC2 scores were in the moderate-serious concerns range (Figure 3), with relatively  
225 greater difficulties with self-absorbed behaviour (a DBC-2 subscale involving diverse items including  
226 mouthing objects, special interests and stereotyped behaviours). On the RBQ, the majority of  
227 participants scored above the threshold for 'normal' levels of repetitive behaviours, and scored  
228 relatively higher on the stereotyped subdomain (Figure 4). Challenging Behaviour Questionnaire  
229 (CBQ, 36) reported rates of self-injury (42.86%), physical aggression (46.43%) and stereotyped  
230 behaviour (50.00%) were high (Supplementary Table 3), but similar to rates observed in other rare  
231 neurogenetic conditions (37,38). The severity of these behaviours also varied, but on average was  
232 similar to those reported in individuals with other rare neurogenetic conditions (39).

233 INSERT FIGURE 2

234 INSERT FIGURE 3

235 INSERT FIGURE 4

236 The majority of CYPs with *CASK*-related disorder are at risk of CVI, according to FCVIQ Sum Scores ( $M$   
237 = 5.10,  $SD = 1.21$ , *range*: 2-6; 90% above cut-off score of 4). Factor scores on the FCVIQ show that  
238 the BINGO *CASK*-related group experienced difficulties with object and face processing, visual  
239 interest, moving in space and anxiety-related behaviours of a level comparable to children with CVI,  
240 whereas clutter and distance viewing might be relatively spared (Figure 5). Broadening to other  
241 aspects of sensory development, most participants scored within the '*like the majority of others*'  
242 range on the Seeking and Avoiding subdomains of the Short Sensory Profile (SSP-2; 40)  
243 (Supplementary Table 4), but within the '*more than others*' and the '*much more than others*' range  
244 on the Sensitivity and Registration subdomains, respectively. The majority of participants also scored  
245 within the '*more than others*' and the '*much more than others*' ranges on the sensory and  
246 behavioural section of the SSP-2, indicating that CYPs with *CASK*-related disorder display more  
247 sensory-related behaviours than most children.

248 INSERT FIGURE 5

## 249 Associations within the BINGO *CASK*-related group

250 Figure 6 and Supplemental Table 5 show the statistical relationships between demographic,  
251 neurological, developmental and social-emotional-behavioural characteristics within *CASK*-related  
252 disorder. We found moderate positive correlations between reversed VABS composite scores and (1)  
253 age ( $r_s = 0.78$ ,  $p.adj < .01$ ), and (2) epilepsy ( $r_{pb} = 0.55$ ,  $p.adj = .03$ ). We also found a moderate  
254 positive correlation between total scores on the DBC2 and RBQ ( $\tau = 0.55$ ,  $p.adj < .01$ ). No other  
255 relationship survived the B-H FDR correction for multiple testing.

256 INSERT FIGURE 6

257 When exploring factors that might contribute to neurodevelopmental variation within *CASK*-related  
258 disorder, we found epilepsy was a significant predictor of adaptive ability ( $F(1, 25) = 10.69$ ,  $p < .001$ ),

259 and explained approximately 27% of the variance in adaptive ability (Supplementary Table 6b). We  
260 also examined whether entering age as a predictor into this model would affect the relationship  
261 between epilepsy and adaptive ability, as we found age was significantly positively correlated with  
262 adaptive ability. The overall model was significant ( $F(2, 24) = 16.38, p < .001$ ) and explained  
263 approximately 54% of the variance in adaptive ability. As shown in Supplementary Table 7b, epilepsy  
264 remained a significant independent predictor of adaptive ability ( $\beta = 11.00, p = .032$ ) and age was  
265 also a significant independent predictor of adaptive ability ( $\beta = 1.56, p < .001$ ).

266 In addition to epilepsy, available data facilitated descriptive exploration of whether neuroanatomical  
267 abnormalities might contribute to neurodevelopmental variation within *CASK*-related disorder. For  
268 the purposes of this analysis, we combined MRI findings into three categories: *MICPCH* (i.e.,  
269 individuals with reported microcephaly and pontocerebellar abnormalities), *Microcephaly* (i.e.,  
270 individuals with reported microcephaly but without reported pontocerebellar abnormalities), and  
271 *Normal* (i.e., individuals without reported microcephaly or neuroanatomical abnormalities).  
272 Individuals for whom no brain abnormality data were available, were classified as *NA*. Groups were  
273 not large-enough for statistical analysis, however, as shown in Supplementary Table 8, average  
274 scores on the VABS composite were similar between individuals with *MICPCH* ( $M = 40.15$ ) and  
275 microcephaly only ( $M = 43.62$ ), but average scores on the motor subdomain of the VABS differed,  
276 whereby individuals with *MICPCH* scored lower ( $M = 30.54$ ) than individuals with microcephaly only  
277 ( $M = 46.88$ ). Parent-reported epilepsy was also more common in individuals with *MICPCH* (53.85%)  
278 than microcephaly only (33.33%). Only two individuals were documented as having no  
279 neuroanatomical abnormalities, hence comparison to this group is not warranted.

## 280 Discussion

281 Previous studies of *CASK*-related disorder are largely based on retrospective medical reports of  
282 individuals identified phenotype-first, with few involving real-time assessments of developmental  
283 ability or social-emotional-behavioural symptoms. To overcome these knowledge gaps for the

284 current and future population of individuals diagnosed with *CASK*-related disorder, we first carried  
285 out a comprehensive review of the published clinical characteristics and compared prevalence rates  
286 to a more recently diagnosed group of CYPs with *CASK* variants (> 60% diagnosed after 2015). We  
287 then evaluated the range of developmental abilities and social-emotional-behavioural problems  
288 within this group, using standardised measures validated for individuals with ID. Lastly, we explored  
289 potential predictors of neurodevelopmental variation within *CASK*-related disorder, to identify  
290 possible markers of prognosis, or mediators of developmental trajectory.

291 Comparison of the BINGO *CASK*-related group to previous literature provides preliminary evidence  
292 for an expanding *CASK*-related phenotype. A lower frequency of developmental delay, severe ID,  
293 and characteristics previously considered typical for *CASK*-related disorder (e.g., MICPCH, optic  
294 atrophy, nystagmus) were observed in the BINGO group, suggesting the within-group distribution of  
295 neurodevelopmental impairments has shifted to include individuals with less severe presentations.  
296 These differences could be attributed to sample ascertainment and measurement. CYPs in BINGO  
297 were recruited genotype-first, with broad inclusion criteria, reflecting identification of patients in  
298 clinical settings i.e. genetic testing for a wide range of developmental concerns, rather than discreet  
299 neuroanatomical or ophthalmological diagnoses. Assessment of ID severity varies between medical  
300 centres and countries due to differing guidelines and practice. Similarly, accessibility of  
301 neuroimaging and reporting of neuroradiological assessments is inconsistent. Adoption of  
302 standardised measures, like the VABS in this study, or routine assessment of neuroanatomy could  
303 help progress our understanding of *CASK*-related characteristics across cohorts and time.  
304 Nevertheless, the clinical spectrum of *CASK*-related disorder within BINGO may more closely reflect  
305 the currently-diagnosed *CASK*-related disorder population.

306 We also identified characteristics associated with *CASK*-related disorder not highlighted in previous  
307 case series, which may require increased clinical attention. For example, sleeping difficulties, such as  
308 regular night waking and difficulty settling, were commonly reported in our sample of CYPs with

309 *CASK*-related disorder, but were not described in previous literature (with the exception of 19).  
310 Specific sleep disorders, along with poor sleep quality, timing, and duration, are common in  
311 individuals with ID and rare genetic syndromes (41–43), and parents of individuals with rare genetic  
312 conditions frequently highlight sleep as a significant area of concern (44,45). Moreover, poor sleep  
313 can be associated with poor adaptive abilities (46,47) and increased challenging behaviour (48–50).  
314 As such, it is possible that poor sleep might contribute to observed adaptive and social-emotional-  
315 behavioural difficulties in CYPs with *CASK*-related disorder. However, the assessment of sleep  
316 difficulties in this study was limited and future studies should strive to generate objective  
317 descriptions of sleep difficulties and specific sleep disorders, as well as factors contributing to sleep  
318 disturbance such as pain or epilepsy, which are imperative for effective management.

319 We also found that the majority of CYPs with *CASK*-related disorder were at risk of CVI (according to  
320 FCIVQ Sum Scores), however clinical assessments are needed to confirm these findings as only 5  
321 participants in this sample had parent-reported CVI. CVI has been commonly reported in other  
322 monogenic conditions with similar genotypic or phenotypic characteristics (51,52). There is a strong  
323 association between CVI and seizures across monogenic conditions, in particular infantile spasms  
324 (52). This may be particularly relevant for *CASK*, as infantile spasms are the most common seizure  
325 type within the group (21).

326 Despite high levels of difficulties across adaptive and social-emotional-behavioural measures, few  
327 significant relationships between measures were identified in the BINGO group of CYPs with *CASK*-  
328 related disorder. In other words, difficulties in one developmental dimension do not necessarily go  
329 alongside difficulties in another dimension, and categorisation of individuals with *CASK*-related  
330 disorder as being mildly or severely affected overall may be overly simplistic. A lack of association  
331 could suggest that different characteristics, for example autism-related traits and CVI, might be  
332 unique dimensions of neurodevelopmental variability in *CASK*-related disorder. However, we only  
333 examined the relationships between total scores on these measures and it is possible that

334 subdomains of autism-related traits and CVI, or specific adaptive functions and challenging  
335 behaviours, might be related. Further analysis of the relationships between dimensions using  
336 additional methods, in a larger *CASK*-related group and over time, are necessary to understand  
337 potential developmental links.

338 Prognostic markers of developmental ability are of interest to parents and clinicians in order to plan  
339 support needs and consider potential interventions. We found that the presence of epilepsy predicts  
340 poorer adaptive ability in *CASK*-related disorder. One possible interpretation is that seizure activity  
341 negatively impacts cognitive development in *CASK*-related disorder, a relationship also observed in  
342 other rare genetic conditions (23–26). Alternatively, epilepsy and poorer adaptive ability might both  
343 reflect altered trajectories of brain development, but are not causally related to one another.  
344 Moreover, anti-seizure medication has been associated with cognitive dysfunction, but evidence of  
345 these effects are mixed in part because of heterogeneities within the paediatric epilepsy population  
346 (53,54). To better understand the possible effects of epilepsy and its treatments on other aspects of  
347 *CASK*-related disorder, neurological data adopting standardised International League Against  
348 Epilepsy classification (55) and quantification of epilepsy severity and medication use plus  
349 longitudinal assessment of cognitive functions are required.

350 In contrast, we did not find descriptive differences in global adaptive ability between individuals with  
351 MICPCH and microcephaly only. This may suggest that cortical abnormalities, rather than hindbrain  
352 abnormalities, contribute to developmental delay and cognition in *CASK*-related disorder. This is  
353 inconsistent with the previous presumption that individuals with MICPCH will be more severely  
354 affected (12,20). However, we observed poorer average motor abilities in CYPs with MICPCH than  
355 those with microcephaly only, confirming contribution of cerebellar abnormalities to motor  
356 development. These findings are observational and MRI data was limited (only available for 50% of  
357 the BINGO *CASK*-related disorder sample). Future studies with comparable MRI data are needed to



358 statistically interrogate the relationships between neuroanatomical abnormality and  
359 neurodevelopmental dimensions in *CASK*-related disorder.

## 360 Conclusions

361 In conclusion, we provide an up-to-date description of the characteristics associated with *CASK*-  
362 related disorder, which includes a diverse range of clinical features, developmental abilities and  
363 social-emotional-behavioural characteristics. We suggest that the group-wise distributions of ID  
364 severity, neuroanatomical features and ophthalmological abnormalities are expanding with broader  
365 ascertainment of individuals with *CASK* variants. The relationships between structural brain  
366 development, epilepsy and developmental trajectories warrant further investigation in this group.

## 367 Abbreviations

368 **AAC:** Augmentative and Alternative Communication

369 **ASD:** Autism Spectrum Disorder

370 **B-H FDR:** Benjamini-Hochberg False Discovery Rate

371 **BINGO:** Brain and Behaviour in Neurodevelopmental disorder of Genetic Origin

372 **CASK:** Calcium/calmodium-dependent serine protein kinase

373 **CNV:** Copy Number Variant

374 **CYP:** Children and Young People

375 **CVI:** Cerebral Visual Impairment

376 **DBC2:** Developmental Behaviour Checklist, Second Edition

377 **FCVIQ:** Flemish Cerebral Visual Impairment Questionnaire

378 **ID:** Intellectual Disability

- 379 **MAGUK:** Membrane-associated Guanylate Kinase
- 380 **MHQ:** Medical History Questionnaire
- 381 **MICPCH:** Microcephaly and pontine cerebellar hypoplasia
- 382 **MRI:** Magnetic Resonance Imaging
- 383 **NGS:** Next Generation Sequencing
- 384 **PECS:** Picture Exchange Communication System
- 385 **RBQ:** Repetitive Behaviour Questionnaire
- 386 **SNV:** Single Nucleotide Variant
- 387 **SRS-2:** Social Responsiveness Scale, Second Edition
- 388 **VABS:** Vineland Adaptive Behaviour Scale
- 389 **XLID:** X-linked Intellectual Disability

## 390 [Declarations](#)

### 391 [Availability of data and materials](#)

392 Anonymised data may be made available to other researchers from the corresponding author on  
393 reasonable request, and on condition of signing a Code of Conduct guaranteeing that the data will  
394 be kept confidential and securely.

### 395 [Ethics declarations](#)

#### 396 [Ethics approval and consent to participate](#)

397 Study protocol was approved by the Cambridge Central Research Ethics Committee (IRAS reference:  
398 11/EE/0330, 'Phenotypes in Intellectual Disability'), and written informed consent was obtained  
399 from each participant's parent/caregiver prior to inclusion.

#### 400 Consent for publication

401 Not applicable

#### 402 Competing interests

403 The authors declare no competing interests.

#### 404 Acknowledgements

405 We thank all of the children and young people with *CASK*-related disorder and their families for their  
406 participation in the BINGO project. We thank the charities who supported our research and  
407 recruitment of participants into the BINGO project, in particular *CASK* Research Foundation, Angelina  
408 *CASK* Neurological Research Foundation, Association Enfants *CASK* France, Unique, Cambridge Rare  
409 Disease Network, and Genetic Alliance UK.

#### 410 Funding

411 This study was funded by the Medical Research Council (MC\_UU\_00030/3), Great Ormond Street  
412 Hospital Charity, and Cambridge NIHR Biomedical Research Centre.

#### 413 Author Information

##### 414 Authors and Affiliations

415 MRC Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, Cambridge,  
416 Cambridgeshire CB2 7EF

417 Jessica Martin, Alkistis Mavroglou-Foti, Josefine Eck, Kate Baker

418 *CASK* Research Foundation, 33 Finchdean Road, Rowlands Castle, Hampshire PO9 6DA

419 Laura Hattersley

420 Department of Medical Genetics, University of Cambridge, Addenbrooke's Treatment Centre,  
421 Cambridge Biomedical Campus, Cambridge, Cambridgeshire CB2 0QQ

422 Kate Baker

423 Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, Cambridgeshire

424 CB2 1QP

425 Kate Baker

## 426 Contributions

427 JM and KB designed and conceptualised the study, with assistance of LH. JM led data collection,

428 supported by AMF and JE. Data analysis and the literature review were conducted by JM and AMF.

429 JM wrote the first draft of the manuscript. AMF wrote parts of the manuscript. KB provided

430 supervision, and reviewed and edited the manuscript. All authors read and approved the final

431 manuscript.

## 432 References

433 1. Pan YE, Tibbe D, Harms FL, Reißner C, Becker K, Dingmann B, et al. Missense mutations in *CASK*,  
434 coding for the calcium-/calmodulin-dependent serine protein kinase, interfere with neurexin  
435 binding and neurexin-induced oligomerization. *J Neurochem*. 2021 May;157(4):1331–50.

436 2. Froyen G, Van Esch H, Bauters M, Hollanders K, Frints SGM, Vermeesch JR, et al. Detection of  
437 genomic copy number changes in patients with idiopathic mental retardation by high-resolution  
438 X-array-CGH: important role for increased gene dosage of *XLMR* genes. *Hum Mutat*. 2007  
439 Oct;28(10):1034–42.

440 3. Hayashi S, Mizuno S, Migita O, Okuyama T, Makita Y, Hata A, et al. The *CASK* gene harbored in a  
441 deletion detected by array-CGH as a potential candidate for a gene causative of X-linked  
442 dominant mental retardation. *Am J Med Genet A*. 2008 Aug 15;146A(16):2145–51.

443 4. Hayashi S, Okamoto N, Chinen Y, Takanashi J ichi, Makita Y, Hata A, et al. Novel intragenic  
444 duplications and mutations of *CASK* in patients with mental retardation and microcephaly with  
445 pontine and cerebellar hypoplasia (MICPCH). *Hum Genet*. 2012 Jan;131(1):99–110.

- 446 5. Hayashi S, Uehara DT, Tanimoto K, Mizuno S, Chinen Y, Fukumura S, et al. Comprehensive  
447 investigation of CASK mutations and other genetic etiologies in 41 patients with intellectual  
448 disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH). Bardoni B, editor.  
449 PLOS ONE. 2017 Aug 7;12(8):e0181791.
- 450 6. Najm J, Horn D, Wimplinger I, Golden JA, Chizhikov VV, Sudi J, et al. Mutations of CASK cause an  
451 X-linked brain malformation phenotype with microcephaly and hypoplasia of the brainstem and  
452 cerebellum. Nat Genet. 2008 Sep;40(9):1065–7.
- 453 7. Hackett A, Tarpey PS, Licata A, Cox J, Whibley A, Boyle J, et al. CASK mutations are frequent in  
454 males and cause X-linked nystagmus and variable XLMR phenotypes. Eur J Hum Genet. 2010  
455 May;18(5):544–52.
- 456 8. Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S, Hardy C, et al. A systematic, large-scale  
457 resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet. 2009  
458 May;41(5):535–43.
- 459 9. Dimitratos SD, Stathakis DG, Nelson CA, Woods DF, Bryant PJ. The Location of HumanCASKat  
460 Xp11.4 Identifies This Gene as a Candidate for X-Linked Optic Atrophy. Genomics. 1998  
461 Jul;51(2):308–9.
- 462 10. Dunn P, Prigatano GP, Szelinger S, Roth J, Siniard AL, Claasen AM, et al. A de novo splice site  
463 mutation in CASK causes FG syndrome-4 and congenital nystagmus. Am J Med Genet A. 2017  
464 Mar;173(3):611–7.
- 465 11. Piluso G, D’Amico F, Saccone V, Bismuto E, Rotundo IL, Di Domenico M, et al. A Missense  
466 Mutation in CASK Causes FG Syndrome in an Italian Family. Am J Hum Genet. 2009  
467 Feb;84(2):162–77.

- 468 12. Moog U, Kutsche K. CASK Disorders. In: GeneReviews® [Internet] [Internet]. Seattle (WA):  
469 University of Washington, Seattle; 2020. Available from:  
470 <https://www.ncbi.nlm.nih.gov/books/NBK169825/>
- 471 13. Becker M, Mastropasqua F, Reising JP, Maier S, Ho ML, Rabkina I, et al. Presynaptic dysfunction  
472 in CASK-related neurodevelopmental disorders. *Transl Psychiatry*. 2020 Sep 14;10(1):312.
- 473 14. Dubbs H, Ortiz-Gonzalez X, Marsh ED. Pathogenic variants in *CASK*: Expanding the genotype–  
474 phenotype correlations. *Am J Med Genet A*. 2022 Sep;188(9):2617–26.
- 475 15. Moog U, Bierhals T, Brand K, Bautsch J, Biskup S, Brune T, et al. Phenotypic and molecular  
476 insights into CASK-related disorders in males. *Orphanet J Rare Dis*. 2015 Dec;10(1):44.
- 477 16. Seto T, Hamazaki T, Nishigaki S, Kudo S, Shintaku H, Ondo Y, et al. A novel *CASK* mutation  
478 identified in siblings exhibiting developmental disorders with/without microcephaly. *Intractable*  
479 *Rare Dis Res*. 2017;6(3):177–82.
- 480 17. LaConte LEW, Chavan V, Elias AF, Hudson C, Schwanke C, Styren K, et al. Two microcephaly-  
481 associated novel missense mutations in *CASK* specifically disrupt the *CASK*–neurexin interaction.  
482 *Hum Genet*. 2018 Mar;137(3):231–46.
- 483 18. LaConte LEW, Chavan V, DeLuca S, Rubin K, Malc J, Berry S, et al. An N-terminal heterozygous  
484 missense *CASK* mutation is associated with microcephaly and bilateral retinal dystrophy plus  
485 optic nerve atrophy. *Am J Med Genet A*. 2019 Jan;179(1):94–103.
- 486 19. Burglen L, Chantot-Bastaraud S, Garel C, Milh M, Touraine R, Zanni G, et al. Spectrum of  
487 pontocerebellar hypoplasia in 13 girls and boys with *CASK* mutations: confirmation of a  
488 recognizable phenotype and first description of a male mosaic patient. *Orphanet J Rare Dis*.  
489 2012;7(1):18.

- 490 20. Moog U, Kutsche K, Kortum F, Chilian B, Bierhals T, Apeshiotis N, et al. Phenotypic spectrum  
491 associated with CASK loss-of-function mutations. *J Med Genet*. 2011 Nov 1;48(11):741–51.
- 492 21. Giacomini T, Nuovo S, Zanni G, Mancardi MM, Cusmai R, Pepi C, et al. CASK related disorder:  
493 Epilepsy and developmental outcome. *Eur J Paediatr Neurol*. 2021 Mar;31:61–9.
- 494 22. Mori T, Zhou M, Tabuchi K. Diverse Clinical Phenotypes of CASK-Related Disorders and Multiple  
495 Functional Domains of CASK Protein. *Genes*. 2023 Aug 20;14(8):1656.
- 496 23. Lindsay N, Runicles A, Johnson MH, Jones EJJ, Bolton PF, Charman T, et al. Early development  
497 and epilepsy in tuberous sclerosis complex: A prospective longitudinal study. *Dev Med Child*  
498 *Neurol*. 2024 May;66(5):635–43.
- 499 24. Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED, et al. Long-term cognitive  
500 outcomes in tuberous sclerosis complex. *Dev Med Child Neurol*. 2020 Mar;62(3):322–9.
- 501 25. Bar C, Breuillard D, Kuchenbuch M, Jennesson M, Le Guyader G, Isnard H, et al. Adaptive  
502 behavior and psychiatric comorbidities in KCNB1 encephalopathy. *Epilepsy Behav*. 2022  
503 Jan;126:108471.
- 504 26. Levy T, Gluckman J, Siper PM, Halpern D, Zweifach J, Filip-Dhima R, et al. Clinical, genetic, and  
505 cognitive correlates of seizure occurrences in Phelan-McDermid syndrome. *J Neurodev Disord*.  
506 2024 May 10;16(1):25.
- 507 27. Takanashi J, Okamoto N, Yamamoto Y, Hayashi S, Arai H, Takahashi Y, et al. Clinical and  
508 radiological features of Japanese patients with a severe phenotype due to CASK mutations. *Am J*  
509 *Med Genet A*. 2012 Dec;158A(12):3112–8.

- 510 28. Valayannopoulos V, Michot C, Rodriguez D, Hubert L, Saillour Y, Labrune P, et al. Mutations of  
511 TSEN and CASK genes are prevalent in pontocerebellar hypoplasias type 2 and 4. *Brain*. 2012 Jan  
512 1;135(1):e199–e199.
- 513 29. Sparrow SS, Cicchetti DV, Saulnier, CA. *Vineland adaptive behavior scales: Third edition*  
514 (Vineland-3). Bloomington: NCS Pearson.; 2016.
- 515 30. Ortibus E, Laenen A, Verhoeven J, De Cock P, Casteels I, Schoolmeesters B, et al. Screening for  
516 Cerebral Visual Impairment: Value of a CVI Questionnaire. *Neuropediatrics*. 2011  
517 Aug;42(04):138–47.
- 518 31. Constantino JN, Gruber CP. *Social Responsiveness Scale–Second Edition (SRS-2)*. Torrance, CA:  
519 Western Psychological Services.; 2012.
- 520 32. Einfeld SL, Tonge BJ. The Developmental Behavior Checklist: The development and validation of  
521 an instrument to assess behavioral and emotional disturbance in children and adolescents with  
522 mental retardation. *J Autism Dev Disord*. 1995 Apr;25(2):81–104.
- 523 33. Moss J, Oliver C. *The Repetitive Behaviour Scale. Manual for administration and scorer*  
524 interpretation. Birmingham, UK: University of Birmingham.; 2008.
- 525 34. Lee NR, Niu X, Zhang F, Clasen LS, Kozel BA, Smith ACM, et al. Variegation of autism related traits  
526 across seven neurogenetic disorders. *Transl Psychiatry*. 2022 Apr 7;12(1):149.
- 527 35. Lubbers K, Stijl EM, Dierckx B, Hageenaar DA, Ten Hoopen LW, Legerstee JS, et al. Autism  
528 Symptoms in Children and Young Adults With Fragile X Syndrome, Angelman Syndrome,  
529 Tuberous Sclerosis Complex, and Neurofibromatosis Type 1: A Cross-Syndrome Comparison.  
530 *Front Psychiatry*. 2022 May 16;13:852208.



- 531 36. Hyman P, Oliver C, Hall S. Self-injurious behavior, self-restraint, and compulsive behaviors in  
532 Cornelia de Lange syndrome. *Am J Ment Retard*. 2002;107(2):146–54.
- 533 37. Arron K, Oliver C, Moss J, Berg K, Burbidge C. The prevalence and phenomenology of self-  
534 injurious and aggressive behaviour in genetic syndromes: Self-injurious behaviour in genetic  
535 syndromes. *J Intellect Disabil Res*. 2011 Feb;55(2):109–20.
- 536 38. Eden KE, de Vries PJ, Moss J. Self-injury and aggression in tuberous sclerosis complex: cross  
537 syndrome comparison and associated risk markers. *J Neurodev Disord* [Internet]. 2014;6(10).  
538 Available from: <https://doi.org/10.1186/1866-1955-6-10>
- 539 39. Bissell S, Oliver C, Moss J, Heald M, Waite J, Crawford H, et al. The behavioural phenotype of  
540 SATB2-associated syndrome: a within-group and cross-syndrome analysis. *J Neurodev Disord*.  
541 2022 Dec;14(1):25.
- 542 40. Dunn W, Little LM, Dean E, Robertson S, Evans B. *The Sensory Profile 2: Short Sensory Profile*.  
543 2nd ed. Pearson; 2014.
- 544 41. Agar G, Brown C, Sutherland D, Coulborn S, Oliver C, Richards C. Sleep disorders in rare genetic  
545 syndromes: a meta-analysis of prevalence and profile. *Mol Autism*. 2021;12(1):1–17.
- 546 42. Surtees ADR, Oliver C, Jones CA, Evans DL, Richards C. Sleep duration and sleep quality in people  
547 with and without intellectual disability: A meta-analysis. *Sleep Med Rev*. 2018 Aug;40:135–50.
- 548 43. Tietze AL, Blankenburg M, Hechler T, Michel E, Koh M, Schlüter B, et al. Sleep disturbances in  
549 children with multiple disabilities. *Sleep Med Rev*. 2012 Apr;16(2):117–27.
- 550 44. Pearson EV, Waite J, Oliver C. Differences in the Information Needs of Parents With a Child With  
551 a Genetic Syndrome: A Cross-Syndrome Comparison. *J Policy Pract Intellect Disabil*.  
552 2018;15(2):94–100.

- 553 45. Trickett J, Heald M, Oliver C. Sleep in children with Angelman syndrome: Parental concerns and  
554 priorities. *Res Dev Disabil*. 2017 Oct;69:105–15.
- 555 46. Cohen S, Fulcher BD, Rajaratnam SMW, Conduit R, Sullivan JP, Hilaire MAS, et al. Behaviorally-  
556 determined sleep phenotypes are robustly associated with adaptive functioning in individuals  
557 with low functioning autism. *Sci Rep*. 2017 Oct 27;7(1):14228.
- 558 47. Brooks LJ, Olsen MN, Bacevice AM, Beebe A, Konstantinopoulou S, Taylor HG. Relationship  
559 between sleep, sleep apnea, and neuropsychological function in children with Down syndrome.  
560 *Sleep Breath*. 2015 Mar;19(1):197–204.
- 561 48. Rzepecka H, McKenzie K, McClure I, Murphy S. Sleep, anxiety and challenging behaviour in  
562 children with intellectual disability and/or autism spectrum disorder. *Res Dev Disabil*. 2011  
563 Nov;32(6):2758–66.
- 564 49. Cohen S, Fulcher BD, Rajaratnam SMW, Conduit R, Sullivan JP, St Hilaire MA, et al. Sleep patterns  
565 predictive of daytime challenging behavior in individuals with low-functioning autism. *Autism*  
566 *Res*. 2018 Feb;11(2):391–403.
- 567 50. Coleman H, Mannion A, Whelan S, Tones M, Heussler H, Bellgard M, et al. Association Between  
568 Challenging Behaviour and Sleep Problems in Adults Enrolled in the Global Angelman Syndrome  
569 Registry. *J Autism Dev Disord* [Internet]. 2024 May 20 [cited 2024 Sep 18]; Available from:  
570 <https://link.springer.com/10.1007/s10803-024-06367-6>
- 571 51. John A, Ng-Cordell E, Hanna N, Brkic D, Baker K. The neurodevelopmental spectrum of synaptic  
572 vesicle cycling disorders. *J Neurochem*. 2021;157(2):208–28.
- 573 52. Shaw E, Flitcroft I, Bowman R, Baker K. Cerebral visual impairment: genetic diagnoses and  
574 phenotypic associations. *J Med Genet*. 2024 Jun;61(6):605–12.

- 575 53. Besag FMC, Vasey MJ. Neurocognitive Effects of Antiseizure Medications in Children and  
576 Adolescents with Epilepsy. *Pediatr Drugs*. 2021 May;23(3):253–86.
- 577 54. Strzelczyk A, Schubert-Bast S. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure  
578 Medications for the Treatment of Developmental and Epileptic Encephalopathies. *CNS Drugs*.  
579 2022 Oct;36(10):1079–111.
- 580 55. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of  
581 the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.  
582 *Epilepsia*. 2017 Apr;58(4):512–21.
- 583 56. Ben Itzhak N, Vancleef K, Franki I, Laenen A, Wagemans J, Ortibus E. Visuo-perceptual profiles of  
584 children using the Flemish cerebral visual impairment questionnaire. *Dev Med Child Neurol*.  
585 2020 Aug;62(8):969–76.
- 586 57. Crotti M, Ortibus E, Mailleux L, Decraene L, Kleeren L, Itzhak NB. Visual, perceptual functions,  
587 and functional vision in children with unilateral cerebral palsy compared to children with  
588 neurotypical development. *Dev Med Child Neurol*. 2024 Aug;66(8):1084–95.
- 589

## 590 Figure legends

591 **Figure 1.** Vineland Adaptive Behaviour Scales - age standardised scores within the BINGO CASK-  
592 related disorder group. *Legend:* ID severity cut-offs are overlaid in red and annotated in black for the  
593 VABS composite score. Mean scores on each measure are represented by the black diamond.

594 **Figure 2.** Social Responsiveness Scale - T-scores within the BINGO CASK-related disorder group.  
595 *Legend:* Severity cut-offs are overlaid in red and annotated in black for the SRS-2 total score. Mean  
596 scores on each measure are represented by the black diamond.

597 **Figure 3.** Developmental Behaviour Checklist - T-scores within the BINGO CASK-related disorder  
598 group. . *Legend:* Levels of concern are overlaid in red and annotated in black for all DBC2 measures.  
599 Mean scores on each measure are represented by the black diamond.

600 **Figure 4.** Restricted and repetitive Behaviour Questionnaire – Scores within the BINGO CASK-related  
601 disorder group. *Legend:* Severity cut-offs are overlaid in red and annotated in black for all RBQ  
602 measures. Mean scores on each measure are represented by the black diamond.

603 **Figure 5.** Flemish cerebral visual impairment questionnaire – Factors scores within the BINGO CASK-  
604 related disorder group. *Legend:* Mean scores for children with CVI (taken from 32) are overlaid in  
605 red, and mean scores for children with CVI and unilateral (taken from 33) are overlaid in blue. Mean  
606 scores on each measure for the BINGO CASK-related group are represented by the black diamond.

607 **Figure 6.** Correlations between demographic and neurodevelopmental domains within CASK-related  
608 disorder.

609

610 **Table 1.** Comparison between reviewed cases and BINGO CASK-related disorder group.

<b>Characteristics (Total; n (%))</b>	<b>Reviewed Cases</b>	<b>BINGO Participants</b>
<i>Sample details</i>		
Sample size	151	31
Females	109 (72.2)	27 (87.1)
Age: range (mean) / months <sup>a</sup>	0.5-588	36-310 (118.8)
<i>Genetic details</i>		
SNV	108/151 (71.5)	20/27 (74.1)
Truncating	47/108 (43.5)	13/20 (65.0)
Missense	38/108 (35.2)	2/20 (10.0)
Intronic	22/108 (20.4)	5/20 (25.0)
CNV	43/151 (28.5)	7/27 (25.9)
Intragenic	28/43 (65.1)	6/7 (85.7)
Multi-gene	14/43 (32.6)	1/7 (14.3)
Uncertain	1/43 (2.3)	0/7 (0.0)
<i>Inheritance</i>		
De novo	68/88 (77.3)	12/15 (80.0)
Inherited	20/88 (22.7)	3/15 (20.0)
Feeding difficulties	56/98 (57.1)	26/31 (83.9)
<i>Tone abnormalities</i>		
Hypotonia	64/112 (57.1)	13/31 (41.9)
Hypertonia	38/91 (41.8)	6/31 (19.4)
Mixed	8/57(14.0)	7/31 (22.6)
<i>OA</i>		
Optic atrophy	32/112 (28.6)	3/31 (9.7)
Strabismus	34/112 (30.4)	8/31 (25.8)
Nystagmus	28/112 (25)	1/31 (3.2)
Other	30/78 (38.5)	18/31 (58.1)
SNHL	28/114 (24.6)	7/31 (22.6)
Seizures	66/135 (48.9)	11/31 (35.5)
<i>DD/ID<sup>b</sup></i>		
Mild/moderate	13/108 (12.0)	17/28 (60.7)
Severe	81/108 (75.0)	7/28 (25.0)
Profound	14/108 (13.0)	4/28 (14.3)
<i>Developmental milestones</i>		
Able to sit	64/113 (56.6)	27/31 (87.1)
Age acquired / months	6-36	7-36
Able to walk	26/101 (25.7)	16/31 (51.6)
Age acquired / months	18-72	13-108
Verbal abilities	23/68 (33.8)	14/31 (45.2)
<i>Brain abnormalities<sup>c</sup></i>		
MICPCH	121/139 (87.1)	11/25 (44.0)
CH and/or PH only	5/139 (3.6)	1/25 (4.0)
MIC and other	4/139 (2.9)	1/25 (4.0)
MIC and CH	3/139 (2.1)	1/25 (4.0)
MIC only	3/139 (2.1)	8/25 (32.0)
Other abnormalities only	0/139 (0.0)	1/25 (4.0)
No abnormalities	3/139 (2.1)	2/25 (8.0)

611 Notes:

612 Absolute frequencies of clinical information are reported with the denominator indicating the  
613 number of individuals for whom information was available.


614 <sup>a</sup> The mean age of individuals in previous papers was not possible to calculate.


615 <sup>b</sup> DD/ID was reported in previous papers using medical reports. In current study, VABS composite  
616 categorised as 'mild/moderate', 'severe' and 'profound' to align with previously reported  
617 classifications was used as a proxy measure of severity of DD/ID.

618 <sup>c</sup> In previous papers, we reported cases where MRI reports were available. In current study,  
619 information about microcephaly and structural brain abnormalities were obtained via MRI, genetic  
620 and parental reports.

621 Abbreviations:

622 CH: cerebellar hypoplasia; CNV: copy number variant; DD/ID: developmental delay or intellectual  
623 disability; MIC: microcephaly; MICPCH: microcephaly with pontine and cerebellar hypoplasia; OA:  
624 Ophthalmological Abnormalities; PH: pontine hypoplasia; SNHL: sensorineural hearing loss; SNV:  
625 single nucleotide variant.







T Score

